Navigation Links
Orthopedics EMR

ProductsOrthopedics EMR
Company OmniMD
Item Orthopedics EMR
Features 
  • Universal Accessibility
  • Informed Decision Making
  • Specialty Specific Customization
  • Ensured Compliance
  • Interpretive Reporting
  • Integrated Workflow
  • Scope for Research Initiatives
    • Description The OmniMD orthopedics EMR addresses the vast information needs of orthopedics specialty. The orthopedics specific EMR includes clinically-defined templates for common orthopedics complaints, history of present illness and review of systems. The system also includes orthopedics specific ICD and CPT Codes that are used to capture accurate charges and quickly generate electronic Superbill at the point of care. To meet specific practice needs, OmniMD offers custom point-and-click templates as well as enhance current orthopedics templates.
    Info OmniMD
    Customer Service: (914) 332-5590
    Web site: http://www.omnimd.com/

    Related medicine products :

    1. HARMONY® Orthopedics
    2. Clinical Orthopedics 2007
    Aurora is a powerful Windows-based digital PSG instrument providing complete data acquisition, recording and review capabilities in one flexible package. The Aurora offers the most feature-packed PSG
    ...eneral purpose stimulator for nerve and muscle sti...le cell to entire muscle stimulation. The two outp...ronized to produce complex paradigms. The outputs ... New features include computer compatibility and f...
    ...rodes with ball joint, and flexible wire with carb...ly, with 16 female support for ball joint of elect...ndividual electrodes with flexible wire and carbon...skull. Mounting post. Key to screw mounting po...
    Features 16 R-2 cotton-wick electrodes in a double-horn assembly for recording from exposed cortex. Each electrode is in a ball and socket joint for ease in positioning. Supporting bone clamp design
    Medicine Products:
    (Date:8/7/2008)...ed levels of prostate-specific antigen (PSA) in th...ostate cancer -- may be biased against obese men, ...this bias may be creating more aggressive cancers ...g to a new study led by investigators in the Duke ...A) Medical Center. , "We know that obese men te...
    (Date:8/7/2008)...irstCall/ -- Eastern Insurance,Holdings, Inc. (Nas...ay that,it has executed a definitive agreement to ...sidiaries ("Employers") in a transaction valued at...tion of $2.9 million in,debt. Employers, wholly ow...pany, an Indianapolis, Indiana-based mono-line wor...
    (Date:8/7/2008)...tCall/ -- GlaxoSmithKline (NYSE:,GSK) today announ...t,once-daily EPZICOM (abacavir + lamivudine) provi...tenofovir DF + emtricitabine) as a first-line opti...ed today at the 17th,International AIDS Conference..., prospective, long-term, head-to-head trial to,ev...
    (Date:8/7/2008)...re-USNewswire/ -- Nurses,consumers, and seniors c...,include a key provision to protect innocent patie...on forthcoming in the closing days of the,legislat...atients have been plagued by the,practice of insur...rance,coverage after they get sick - so called "re...
    Breaking Medicine News(10 mins):Health News:PSA screening may be biased against obese men, leading to more aggressive cancers 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 3Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 4Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 2Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 4Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 5Health News:Consumers, Nurses, Seniors Tell Governor: Don't Break Your Promise to Protect Innocent Patients from Health Insurance Cancellations, Don't Weaken Existing Law 2Health News:Consumers, Nurses, Seniors Tell Governor: Don't Break Your Promise to Protect Innocent Patients from Health Insurance Cancellations, Don't Weaken Existing Law 3Health News:Consumers, Nurses, Seniors Tell Governor: Don't Break Your Promise to Protect Innocent Patients from Health Insurance Cancellations, Don't Weaken Existing Law 4
    ... cholera epidemic has swept through Angola coverin...anza Norte. Since the declaration of the cholera ...ses has risen to 2,026 with a death toll of 48. //...atoumata Diallo handed over 7 tons of medicine an...
    ...ecent clinical study showed that ROZEREM? (ramelte...om chronic insomnia, as the medication is found to...antly. // It has also been found that patients who...ing or withdrawal effects. In this placebo-contro...
    ...rian cancer claims more deaths than any other canc...re expected in US this year, says the National Can... mammograms are used for screening, the option is ...vic examination can detect ovarian cancer, that to...
    ...Australian research team led by Dr Josephine Bowle...or Molecular Bioscience at The University of Queen...hind why males produce sperm and females produce e...c journals Science. This discovery is of great val...
    Other Medicine News:Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 2Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 3Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 4
    (Date:8/8/2008)...T SETAUKET, N.Y., Aug. 8 /-...Board: LIXT) announced today,that lead compounds f...eloped as potential treatment for specific types o...atic cancers in a mouse model., Dr. John S. Kovac...usly,reported that lead compounds from each of two...
    (Date:8/7/2008)...cept Pharmaceuticals is Advancing Bile Acid-Derive...s in Treating Metabolic Diseases, NEW YORK, Aug. ...en,recognized primarily as natural detergents that...lesterol homeostasis. However, recent research,adv...r systemic endocrine,functions, acting as importan...
    (Date:8/6/2008)...NTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ ...eported today financial results for,the quarter an...d an update,on the Company,s progress with its pro...quarter and six month period ended June 30, 2008, ...es generally accepted in the United,States (GAAP),...
    (Date:8/6/2008)...Trial Demonstrated the Safety and Efficacy of the ... Capsule, JERUSALEM, Israel, August 6 /PRNewswire...: ORMP)( http://www.oramed.com ), a developer of,o...esults from the clinical,trial of its oral insulin...he product had a good safety profile and was well ...
    Breaking Medicine Technology:Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer 2Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling 2Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling 3Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 2Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 3Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 4Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 5Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 6Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 7Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 8Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 9Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 10Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 11Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule 2AHRQ Releases Toolkits to Help Providers and Patients Implement Safer Health Care Practices 7666 1AHRQ Releases Toolkits to Help Providers and Patients Implement Safer Health Care Practices 7666 2New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 7664 1New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 7664 2Genes Yield More Clues to Schizophrenia 7662 1Genes Yield More Clues to Schizophrenia 7662 2Pheromones identified that trigger aggression between male mice 7660 1Pheromones identified that trigger aggression between male mice 7660 2Pheromones identified that trigger aggression between male mice 7660 3
    ...SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ ... wholly-owned,subsidiary of Neurochem Inc. , annou...M) published the results of the "Eprodisate,For AA...ark,clinical trial in the search for a treatment o...clinical trial for eprodisate,(KIACTA(TM)) demonst...
    ...) is evaluating zonisamide SR as a novel component..., June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen...any focused on the,treatment of central nervous sy...oday announced results from a Phase I trial evalua...prietary,sustained-release (SR) formulation of zo...
    Other Medicine Technology:Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 2Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 3Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 4Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 5OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4